It depends on the standard you follow. As of September 2026, Iovance Biotherapeutics, Inc. (IOVA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.88% / 30% · Interest income / Revenue 1.90% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.88% / 33% · Receivables / Mkt Cap (36m) 2.24% / 49% · Interest income / Revenue 1.90% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.88% / 33.33% · Receivables / Mkt Cap (24m) 2.24% / 33.33% · Interest income / Revenue 1.90% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 1.31% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 34.3% / 33.33% · Receivables / Avg Assets (4Q) 9.97% / 33.33% · Interest income / Revenue 1.90% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 38.0% / 33.33% · (Cash+Recv) / Total Assets 48.8% / 33.33% · Interest income / Revenue 1.90% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Iovance Biotherapeutics, Inc. (IOVA) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Iovance Biotherapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.90% of each dividend: Iovance Biotherapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a Healthcare company (Biotechnology) with a market capitalization of $3.5B. The Maz Rating grades it against the other companies in its sector.
Iovance Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.55, Iovance Biotherapeutics, Inc. trades at 9.2x sales and 4.2x book value. Over the last twelve months it generated about $379M of revenue and a net loss of $245M. It runs a gross margin of 53.2%, an operating margin of -60.8% and a net margin of -58.2%. It shows return on equity of -29.7%, return on invested capital of -25.8% and a free cash flow yield of -6.2%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 5.20. Over the past 52 weeks the share price ranged from $2.08 to $15.37, with a beta of 0.76.
Iovance Biotherapeutics, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 15 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.